BPB ALERT: DIGITAL THERAPY PROGRAM FOR FIBROMYALGIA…

BACK PAIN BLOG UK...

TechCrunch wrote that Swing Therapeutics, a digital therapeutics startup, has received an FDA breakthrough device designation for their 12-week smartphone-assisted fibromyalgia management program. This is the company’s first breakthrough designation, and precedes a deluge of clinical trials scheduled for this year. 

Swing Therapeutics was founded in 2019 and has raised a total of $9 million in seed funding led by JAZZ Venture Partners. The company is focused on managing chronic pain, and specifically fibromyalgia.

This FDA breakthrough designation was awarded to the company’s smartphone adaptation of an acceptance and commitment therapy (ACT) program originally designed and tested at the University of Manitoba. Swing Therapeutics has exclusively licensed the program, and adapted it to form their own phone-based version.

“We basically used [The University of Manitoba program] as a basis for our program and then really built on top of it, and adapted it to a sort of…

View original post 129 more words

Published by peter petterson

Father of four, grandfather of thirteen, and great-grandfather of eight. Resides in Taita, Lower Hutt, Wellington, New Zealand. Living happily in retirement and enjoying the company of my many young descendants.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Create your website with WordPress.com
Get started
%d bloggers like this: